The identification of gut microbial markers associated with immunotherapy response in melanoma represents a significant advancement in personalized medicine. This could lead to improved patient stratification and treatment outcomes, necessitating that pharma companies integrate microbiome profiling into their clinical development programs. Regulatory context from FDA (Oncology (Cancer)/Hematologic Malignancies Approval Notifications) supports the near-term read. Assessment grounded in 9 ranked evidence items (2 high-relevance).